Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

138
Feng, ZidingFred Hutchinson Cancer Research Center
Annexin, LAMR1, PGP
Proteomics
Lung and Upper Aerodigestive Cancers Research Group
2

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

Aim 1: To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis. Aim 2: To identify additional antigens and antibodies in sera from CARET participants, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, and histologic type. Aim 3: To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
Natural Array technique

Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

32nd SC Meeting
Thank you to everyone who made the 32nd EDRN Steering Committee meeting a success. The next event is the 10th EDRN Scientific Workshop from March 6-8, 2018 in Bethesda, MD. More information about this Workshop will be sent soon. Click here to view the flyer.
EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.